Nabiximols (Sativex) for agitation in Alzheimer's dementia: feasibility trial (STAND)

Introduction and clinical context

The study Nabiximols (Sativex) for agitation in Alzheimer's dementia: feasibility trial (STAND) (PMC · 2024) is part of the scientific research on the use of cannabinoids in alzheimer.

In Alzheimer's disease and other dementias, part of the cannabinoid research focuses on neuropsychiatric symptoms — especially agitation and aggression —, which are hard to manage and affect patients and caregivers. Synthetic cannabinoids (such as dronabinol and nabilone) and nabiximols have been evaluated in trials, with signs of benefit in some studies. In elderly people with dementia, safety is a priority, requiring low doses and close follow-up.

Understanding what science shows about the use of cannabinoids in alzheimer helps patients and healthcare professionals make safer, well-founded decisions, based on evidence rather than common sense.

Methodology and findings

This clinical trial was conducted in a controlled manner, comparing the treatment with a reference group. Randomized, double-blind, placebo-controlled feasibility trial of nabiximols in UK care homes. The blinded, controlled design reduces bias and increases the reliability of the finding. Results from controlled trials like this are especially valuable for guiding therapeutic decisions.

Mechanism of action and safety

In dementias, the most studied therapeutic target is neuropsychiatric symptoms. Cannabinoids such as dronabinol and nabilone, and nabiximols, act on CB1 receptors, modulating agitation and behavior. Safety is central in this elderly, frail population: sedation, dizziness, hypotension and fall risk, in addition to interactions from polypharmacy. THC's psychoactive effects can worsen confusion in some patients. It is recommended to start with very low doses, titrate slowly and monitor closely, weighing risk and benefit case by case.

Regulation in Brazil (Anvisa)

In Brazil, access to cannabis products is regulated by Anvisa — mainly through RDC 660/2022 (patient import with a medical prescription) and the new manufacturing and import framework, RDC 1,015/2026. Any therapeutic use must start from an individualized medical assessment and prescription. This content is informative and scientific and does not replace the guidance of a healthcare professional.

This is informative content produced by Brazcann; for the full methodology and detailed results, consult the original publication (PMC · 2024). Access to cannabis treatments must always occur through the regulated pathway, with a prescription and medical follow-up.

Frequently asked questions

Does cannabis treat Alzheimer's?

The research focuses on symptoms such as agitation, not on a cure; use in the elderly requires caution and follow-up.

Which symptoms are studied?

Mainly neuropsychiatric symptoms, such as agitation and aggression.